Praxis Precision Medicines, Inc. (PRAX) News
Follow Praxis Precision Medicines, Inc. (PRAX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Praxis Precision Med Price Target Maintained With a $1201.00/Share by HC Wainwright & Co.
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 10:36 AM UTC
L
Praxis Precision Med Price Target Maintained With a $582.00/Share by Needham
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 09:55 AM UTC
L
Praxis Precision Medicines announces Nasdaq Rule 5635(c)(4) inducement grants
Praxis Precision Medicines said its Board Compensation Committee approved inducement grants under Nasdaq Listing Rule 5635(c)(4) on September 1, 2026.
EQUITY | Sep 03, 2026, 08:08 PM UTC
L
Praxis Precision Medicines announces Nasdaq Rule 5635(c)(4) inducement grants
Praxis Precision Medicines, Inc. announced inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 03, 2026, 08:01 PM UTC
H
Motorola Solutions Posts Upbeat Q2 Earnings, Joins Insmed, Diodes, Parker-Hannifin And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Thursday. Shares of Motorola Solutions In c (NYSE: MSI ) rose sharply after the company reported better-than-expected second-quarter financial
EARNINGS | Aug 06, 2026, 02:01 PM UTC
L
PRAX - Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results
PRAX - Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results
EARNINGS | Aug 06, 2026, 12:01 PM UTC
L
PRAX - Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
PRAX - Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
EARNINGS | Jul 30, 2026, 08:02 PM UTC
M
Praxis Precision Medicines Announces FDA Extends PDUFA Date To December 27, 2026 For Relutrigine Following Major Amendment Submission; No Ne
FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX ), a fully integrated, leading central nervous system (CNS) precision neuroscience
REGULATION | Jun 29, 2026, 08:35 PM UTC
H
PRAX Seeks Faster Development
Praxis Precision Medicines' seizure drug elsunersen receives Breakthrough Therapy Designation from the FDA after positive trial results
EQUITY | Jun 22, 2026, 05:29 PM UTC
H
PRAX: FDA Grants Breakthrough Therapy
Praxis Precision Medicines receives Breakthrough Therapy designation from FDA for Elsunersen to treat seizures associated with SCN2A development and epileptic encephalopathy
REGULATION | Jun 22, 2026, 12:10 PM UTC
H
PRAX Receives FDA Breakthrough
Praxis Precision Medicines receives FDA Breakthrough Therapy Designation for Elsunersen to treat seizures associated with SCN2A developmental and epileptic encephalopathy
EQUITY | Jun 22, 2026, 12:02 PM UTC